Good MorningEquity markets started the weak on stable footing but could not post substantial gains on Monday. The move is partly due to easing fear of a banking crisis compounded by uncertainty about the PCE data on Friday. The analysts expect core PCE to moderate to 0.4% month-to-month but remain hot at 4.7% YOY. At this level, the FOMC may need to hike interest rates beyond the recently intended target, and there is a risk it will come in hotter than expected.
With only 2 weeks until the start of the Q2 peak earnings reporting cycle, the market is bracing for what could be a very bad season. The consensus target for Q1 earnings is below -6.0% and it could be worse by the end of the season. The details that will more the market are the guidance and outlook for the 2nd half of the year, if those take another hit this market will move one step closer to another major sell-off. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
For the last year, investors have heard the advice that “cash is king.” Cash is also important when it comes to the companies you choose to invest in. And while this is a difficult market, there are still opportunities for buy-and-hold investors with a suitable time horizon. And the th... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Technology | |
While the enterprise software makers are in the doldrums, and the financial sector tries to recover from a battering, a few specialty software firms, including Intapp Inc. (NASDAQ: INTA), Vertex Inc. (NASDAQ: VERX), and GuidewIre Software Inc. (NYSE: GWRE) are headed toward greater profitability, ... Read the Full Story |
|
Healthcare | |
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company’s stock is up 7.3% in the last month and just announced some news that could send the stock much higher.
Speci... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | |
Analysts can be a powerful force in the market. If there are enough of them covering a stock, when their sentiment changes, it will move the stock price. Marketbeat.com’s analyst tracking tools will show 3 names that reported solid results for CQ4, gave positive guidance, and earned a round ... Read the Full Story |
|
Healthcare | |
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies’ jointly developed medication Dupixent.
In Phase 3 clinical trials, Dupixent reduced severe ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Finance | |
Want Diversified Exposure in the Regional Banks? Try These ETFs
The First Republic Bank crisis and the possible contagion it could bring has the entire financial services industry down compared to a month ago, but this is an opportunity for investors. There is risk in the financial sector, bu... Read the Full Story |
|
Consumer Discretionary | |
Carnival Cruise Lines (NYSE: CCL) has been weathering stormy seas for the last 2 years, but the skies are clearing, and smoother sailing is ahead. The headwinds are not over, but signs within the Q1 earnings report point to a return to normalcy that includes positive cash flow and debt reduction. ... Read the Full Story |
|
Finance | |
The market has been selling off bank stocks on fears of contagion stemming from the Silicon Valley Bank implosion and Signature Bank insolvency. Regional banks were the victims of panic selling. After the Credit Suisse Group AG (NYSE: CS) bailout by UBS Securities, there are rumblings of potential... Read the Full Story |
|
Healthcare | |
BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. While COVID sales have slowed, this company is not dependent on COVID ... Read the Full Story |
|
Markets | |
The bad news: Gap, Inc. (NYSE:GPS) shares are down 20% year-to-date and more than 70% from their post-Covid peak.
The good news: the clothes retailer now offers a stylish accessory in the form of a 6.8% forward dividend yield.
As the apparel industry adjusts to ‘new norms’ in the w... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
